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Genome-wide association studies (GWAS) have identified numerous variants underlying cardiovascular diseases 
including stroke and coronary heart disease.1,2 However, in 
the main, the mechanism of these variants on disease risk 
has been elusive. A complementary approach to the standard 
GWAS design of clinical end points such as stroke is to in-
tegrate data with GWAS on intermediate phenotypes of di-
sease risk such as carotid intima-media thickness or plaque.3 
Identifying variation that is common to an intermediate phe-
notype and disease outcome has the potential to identify 
mechanism-specific associations with disease and to illumi-
nate causal pathways.
Endothelial function is one such phenotype of importance 
to stroke.4 The endothelium is a group of cells lining blood 
vessels that functions both as a barrier, controlling the passage 
of materials into and out from the blood stream, and as a signal 
transducer, regulating vessel structure and function.5 Impaired 
endothelial function is involved in the initiation of atheroscle-
rosis, as well as latter plaque instability,6 and promotion of 
small vessel arteriopathy.7,8 Several techniques exist for meas-
uring endothelial function in vivo.5 One validated method, 
ultrasound flow-mediated dilatation (FMD), measures the re-
sponse of the arterial endothelium to reactive hyperemia via 
inflation and subsequent deflation of a blood flow constricting 
cuff (sphygmomanometer).5
Here, we perform a GWAS of FMD in adolescents from 
ALSPAC (Avon Longitudinal Study of Parents and Children). 
We integrate the results with a large-scale GWAS of stroke 
in over 60 341 cases and 452 969 controls (MEGASTROKE)2 
and use genome-wide colocalization approaches to identify 
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Abstract—We aimed to characterize the genetics of endothelial function and how this influences risk for cardiovascular 
diseases such as ischemic stroke. We integrated genetic data from a study of ultrasound flow-mediated dilatation of 
brachial artery in adolescents from ALSPAC (Avon Longitudinal Study of Parents and Children; n=5214) with a study 
of ischemic stroke (MEGASTROKE: n=60 341 cases and 452 969 controls) to identify variants that confer risk of 
ischemic stroke through altered endothelial function. We identified a variant in PDE3A (Phosphodiesterase 3A), encoding 
phosphodiesterase 3A, which was associated with flow-mediated dilatation in adolescents (9–12 years of age; β[SE], 
0.38 [0.070]; P=3.8×10−8) and confers risk of ischemic stroke (odds ratio, 1.04 [95% CI, 1.02–1.06]; P=5.2×10−6). 
Bayesian colocalization analyses showed the same underlying variation is likely to lead to both associations (posterior 
probability, 97%). The same variant was associated with flow-mediated dilatation in a second study in young adults 
(age, 24–27 years; β[SE], 0.47 [0.23]; P=0.047) but not in older adults (β[SE], −0.012 [0.13]; P=0.89). We conclude 
that a genetic variant in PDE3A influences endothelial function in early life and leads to increased risk of ischemic 
stroke. Subtle, measurable changes to the vasculature that are influenced by genetics also influence risk of ischemic 
stroke.  (Hypertension. 2020;75:365-371. DOI: 10.1161/HYPERTENSIONAHA.119.13513.) 
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genetic variation that contributes to stroke through impaired 
endothelial function in adolescents.
Methods
Data used in this study are available to all researchers through appli-
cation to ALSPAC (http://www.bristol.ac.uk/alspac/researchers/) and 
UK Biobank (https://www.ukbiobank.ac.uk/register-apply/). Publicly 
available GWAS data pertaining to cardiovascular risk factors and 
traits used in this study are available from http://megastroke.org 
(stroke), https://www.cardiomics.net/download-data (coronary heart 
disease), http://www.diagram-consortium.org/downloads.html (type 
2 diabetes mellitus), http://www.broadcvdi.org/ (atrial fibrillation), 
http://lipidgenetics.org/ (lipids), and https://conservancy.umn.edu/
handle/11299/201564 (smoking status).
Study Subjects
Study Populations are outlined in Table 1. Pregnant women resident in 
Avon, UK with expected dates of delivery April 1, 1991, to December 
31, 1992, were invited to take part in ALSPAC—a prospective obser-
vational study of the genetic and environmental determinants of de-
velopment and health from the prenatal period into adulthood.9–11 The 
initial number of pregnancies enrolled was 14 541, which was later 
increased to 15 247 by retrospective recruitment. A total of 15 656 
fetuses were included in further studies, of which 14 889 were alive 
at 1 year of age. Please note that the ALSPAC study website contains 
details of all the data that are available through a fully searchable data 
dictionary and variable search tool (http://www.bristol.ac.uk/alspac/
researchers/our-data/). We studied endothelial function in 7557 of 
these children aged between 9 and 12 years (mean [SD], 10.7 [0.25] 
years). Age, sex, body mass index, blood pressure, and environmental 
factors were collected as described previously.9 Room and skin tem-
peratures were assessed using a commercial digital thermometer 
immediately before the vascular examination. Brachial artery en-
dothelial function was successfully measured in 88% of children by 
FMD.11 The right brachial artery was imaged using high-resolution 
ultrasound (ALOKA 5500) 5 to 10 cm above the antecubital fossa 
with the probe held in a stereotactic clamp. Edge detection software 
(Brachial Tools, MIA, IA) was used to measure the brachial artery 
diameter at 3-second intervals throughout the 11-minute recording 
protocol. Brachial artery FMD was induced by a 5-minute inflation 
of a pneumatic cuff to 200 mm Hg, around the forearm immediately 
below the medial epicondyle followed by rapid deflation using an 
automatic air regulator (Logan Research, United Kingdom). We used 
FMD expressed as a percentage calculated using peak diameter in 
response to reactive hyperemia in relation to the baseline diameter.12
Genotyping and Quality Control in ALSPAC
We used imputed genotypic data of the ALSPAC. Genotyping, quality 
control, and imputation has been described previously.13 GWAS data 
were generated by Sample Logistics and Genotyping Facilities at 
Wellcome Sanger Institute and LabCorp (Laboratory Corporation of 
America) using support from 23andMe. Imputation was performed 
using the complete reference panel from the third phase of the 1000 
Genomes Project.14 Five thousand two hundred ninety-seven chil-
dren had both genotyping information and FMD measurements. We 
excluded 83 cryptically related samples with PI-HAT >0.1875, deter-
mined using PLINK2,15 meaning the final analyses were performed 
on 5214 samples. We analyzed all single-nucleotide polymorphisms 
(SNPs) that were polymorphic (minor allele frequency, >1%) in 
European samples and had an imputation info value >0.5. PLINK2 
was used to estimate identity-by-descent and to perform ancestry-
informative principal components (PC) analysis.15
MEGASTROKE Genome-Wide Summary Statistics
We used summary statistics, downloaded from http://megastroke.
org, derived from MEGASTROKE—a transethnic genome-wide 
meta-analysis of stroke.2 Our primary analysis was for all ischemic 
stroke cases versus controls (60 341 cases and 452 969 controls). 
We also explored associations with ischemic stroke subtypes in 
MEGASTROKE: cardioembolic stroke (9006 cases and 426 629 
controls), large artery stroke (6688 cases and 345 446 controls), and 
small vessel stroke (11 710 cases and 346 101 controls).
Genome-Wide Analyses in Adolescents From 
ALSPAC
Per-allele β-coefficients and SEs for FMD were generated in a regres-
sion model that included age, sex, room temperature, body tempera-
ture, and 8 ancestry-informative PCs. Covariates were selected based 
on their significant association with FMD in previous ALSPAC publi-
cations.11 For sensitivity analysis, we performed analysis of a second 
model that was additionally adjusted for heritable covariates: body 
mass index, systolic blood pressure, and diastolic blood pressure. All 
statistical tests conducted were 2 sided, and SNPTEST v2.5.4-beta3 
was used to perform the analysis. We used a P threshold of 5.0×10−8 
to determine statistical significance. We discarded significant low-
frequency SNPs (minor allele frequency, <0.05) without substantial 
linkage disequilibrium support (1 region).
Validation Datasets
We explored validation of the FMD-associated novel SNP in inde-
pendent cohorts of FMD measured in both younger and older cohorts 
of subjects.
We sought replication in younger subjects in YFS (Young Finns 
Study)—a study of young subjects (age, 24–45 years).16 The YFS co-
hort is a Finnish longitudinal population study sample on the evolu-
tion of cardiovascular risk factors from childhood to adulthood. In the 
present study, we used the variables measured in 2001 and described 
in detail previously.17 For these subjects, genotyping was performed 
in 2009 using a custom-built Illumina Human 670k BeadChip at the 
Welcome Trust Sanger Institute and imputed to 1000 Genomes phase 
3.18 We attempted replication of a single SNP in the youngest quar-
tile (age, 24–27 years) and overall (age, 24–45 years). All analyses 
included age, sex, center, and ancestry-informative PCs as covariates.
We sought replication of the novel SNP with FMD in older in-
dividuals of European ancestry in both the FHS (Framingham Heart 
Study) and the MESA (Multi-Ethnic Study of Atherosclerosis).
The MESA subjects analyzed were 1029: 50% men; mean age, 61 
years (SD, 10 years). Flow-mediated dilation (FMD) of the brachial 
artery mean (SD), 4.8 (3.1). FHS subjects analyzed were 393: 38% 
men; mean age, 41 years (SD, 8 years). FMD of the brachial artery 
mean (SD), 5.9 (3.7).
For the MESA cohort, analysis was restricted to subjects 
with European ancestry based on the self-reported race/ethnic-
ity. MESA and FHS genotype panels are described elsewhere.19,20 
Standard quality control procedures for the genotype data were 
performed using PLINK. We excluded SNPs with a minor allele 
frequency <5% or significant deviation from Hardy-Weinberg e-
quilibrium (P<1.0×10−6). SHAPEIT and IMPUTE2 software were 
used to impute PDE3A (Phosphodiesterase 3A) region (chr 12; 
p12.2:18060181-23060180; GRCh v37), using the 1000 Genomes 
reference panel (GRCh v37, phase III).18 Imputed SNPs with an im-
putation quality estimate (R2<0.40) were removed for association 
tests. The first 3 PCs for population structures were derived using 
the smartpca script in EIGENSTRAT and included as covariates in 
association analyses for both MESA and FHS.21
For both cohorts, linear regression analyses assuming an additive 
model were computed using 2 models: model 1 that included sex, 
age, and PCs 1 to 3 and model 2 where body mass index, diastolic 
blood pressure, and systolic blood pressure at the time of the mea-
surements were added to the covariates of model 1. Linear mixed-
effects Kinship models (package lmekin in R) for family data were 
implemented in FHS.
Further Analysis of Novel Association
We used a Bayesian test for colocalization at the novel gene between 
FMD GWAS summary results and stroke to assess whether 2 associ-
ation signals are consistent with a shared causal variant.22 The gwas-
pw package was used to perform all analyses (https://github.com/
joepickrell/gwas-pw).
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Association With Cardiovascular Risk Factors, 
Outcomes, and Coronary Artery Expression
Using data from publicly available repositories and UK Biobank, we 
assessed the impact of the PDE3A rs11045239 variant on cardiovas-
cular risk factors: systolic blood pressure (id 4080), diastolic blood 
pressure (id 4079), pulse pressure (derived from the former 2 variables), 
pulse wave arterial stiffness (id 21021), hypertension (self-reported, id 
200002=1465), hypercholesterolemia (self reported: id 20002=1473), 
ever smoking,23 as well as cardiovascular diseases: coronary artery di-
sease,24 type 2 diabetes mellitus,25 and atrial fibrillation.26
UK Biobank (http://www.ukbiobank.ac.uk) is a prospective study 
that recruited 500 000 community-dwelling participants aged 40 to 69 
years from across the United Kingdom between 2006 and 2010. The 
study collects extensive data from questionnaires, interviews, health 
records, physical measures, biological samples, and imaging. For all 
variables we considered in this analysis, we excluded outlier readings 
that were >3 SDs from the median value.
The UK Biobank genotyping procedure has been described else-
where.27 In short, 2 custom genotyping arrays were used to genotype 
49 950 (UK BiLEVE Axiom Array) and 438 427 participants (UK 
Biobank Axiom Array).27,28 Genotype data (805 426 markers) were a-
vailable for 488 377 individuals and were subsequently imputed to the 
Haplotype Reference Consortium reference panel (39 131 578 autoso-
mal SNPs). Imputed genotypes were available for 487 442 individuals 
in this study.27 From the resulting imputed dataset, we excluded (1) 
individuals who did not segregate with European individuals based 
on PC analysis, (2) individuals with high levels of heterozygosity or 
missingness (>5%), and (3) individuals whose reported sex did not 
match with sex inferred from the genetic data.
All UK Biobank analyses included age, sex, and ancestry-infor-
mative PC as covariates. In analyses of blood pressure variables, we 
additionally corrected for body mass index, as has been the conven-
tion in GWAS studies.29
In addition, we investigated the association of rs11045239, and 
other variants in close linkage disequilibrium (r2>0.8), calculated us-
ing LDlink,30 with expression of PDE3A in coronary arteries from 
Genotype-Tissue Expression.31 All analyses were performed using 
the Genotype-Tissue Expression portal (https://gtexportal.org/home/; 
accessed May 14, 2019).
Standard Protocol Approvals, Registrations, and 
Patient Consents
Ethical approval for the study was obtained from the ALSPAC Ethics 
and Law Committee and the Local Research Ethics Committees. UK 
Biobank received ethical approval from the research ethics commit-
tee (reference 11/NW/0382). All participants provided informed con-
sent to participate. The present analyses were conducted under UK 
Biobank application number 36509.
Results
We performed a genome-wide association analysis of FMD in 
5214 adolescents from ALSPAC. The inflation of test statistic 
using genomic control was 1.014, while the linkage disequi-
librium score regression intercept was 1.001 indicating no in-
flation of test statistics.1 We identified an SNP (rs11045239) 
on chromosome 12 (12:20579694) that was associated with 
FMD (β[SE], 0.38 [0.070]; P=3.8×10−8). The risk allele (A) 
had a frequency of 40% among Europeans, and the SNP was 
located in an intron of the PDE3A gene, which encodes phos-
phodiesterase 3A—a member of the cyclic GMP (cGMP)–
inhibited cyclic nucleotide phosphodiesterase family.
To identify regions with evidence of shared genetic vari-
ation impacting on FMD and ischemic stroke, we performed 
a genome-wide Bayesian colocalization analysis.22 This anal-
ysis highlighted 1 region around the same PDE3A gene where 
the underlying genetic variation was highly likely to be asso-
ciated with both FMD and ischemic stroke (posterior proba-
bility, 97%; Figure 1). The most likely causal SNP based on 
Bayesian colocalization was rs11045239, although this was not 
Figure 1. Colocalization of Genetic 
Associations with Flow Mediated Dilation and 
Ischaemic Stroke at PDE3A Locus. Plots of 
−log10(P) for association of single-nucleotide 
polymorphisms (SNPs) in the PDE3A gene 
region. Each point indicates an SNP association 
with the trait, with color indicating correlation 
(r2) with the lead SNP, rs11045239. Red line 
indicates recombination rate (CM/Mb) at this 
region of the genome. A, SNP associations 
with flow-mediated dilatation by chromosome 
position. B, SNP associations with ischemic 
stroke by chromosome position.
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conclusive (posterior probability, 65%). The 95% credible set 
contained 4 other SNPs: rs12811752, rs11045244, rs7489190, 
and rs10841519. The same PDE3A locus was recently reported 
to be associated at genome-wide significance with ischemic 
stroke in MEGASTROKE (lead SNP, rs7304841; odds ratio, 
1.05 [95% CI, 1.03–1.07]; P=4.9×10−8).2 Effects were similar 
across ischemic stroke subtypes: cardioembolic stroke (odds 
ratio, 1.04 [95% CI, 1.00–1.08]), large artery stroke (odds ratio, 
1.05 [95% CI, 1.00–1.10]), and small vessel stroke (odds ratio, 
1.05 [95% CI, 1.01–1.08]). No other regions were highlighted 
with posterior probability of shared genetic effects >50%.
Having established that genetic variation in a single locus 
in PDE3A is associated with both ischemic stroke and FMD, 
we sought validation of the association in other cohorts with 
FMD data. As no other cohorts with genetic data and FMD 
measurement in adolescents exist to our knowledge, we sought 
replication in adult populations. In the YFS, we first analyzed 
the youngest individuals (the first quartile, 24–27 years; 
n=599) who most closely resemble the discovery cohort. In 
these individuals, there was evidence at nominal significance 
that the variant was associated with disease (β[SE], 0.47 
[0.23]; P=0.047). Conversely, when considering the whole 
cohort (age, 24–45 years; n=2337), we did not observe a sig-
nificant effect (β[SE], 0.14 [0.13]; P=0.25). We also explored 
whether the same variant was associated with FMD in older 
individuals from the FHS and MESA (n=1186). We found no 
evidence of an association in this older group (β[SE], −0.012 
[0.13]; P=0.89). These results might indicate that the genetic 
variant identified in the study has different influence on endo-
thelial function in adolescents compared with adults.
To establish whether variation in PDE3A was associated 
solely with endothelial function, or influenced other cardio-
vascular pathways, we looked at association of the PDE3A 
rs11045239 SNP with other cardiovascular risk factors and 
outcomes in large publicly available datasets and UK Biobank. 
The PDE3A rs11045239 variant was not associated with any 
other related cardiovascular traits or outcomes (all P>0.05; 
Figure 2), suggesting the association with ischemic stroke is 
not mediated through alternative cardiovascular pathways.
In addition, we looked at the association of PDE3A SNP 
rs11045239 and its proxies with mRNA expression of PDE3A 
in coronary arteries from Genotype-Tissue Expression. 
Although rs11045239 was not significantly associated with 
PDE3A expression (P=0.075), all proxy SNPs showed as-
sociation at P<0.05 (Table 2). The A allele association with 
increased FMD and risk of stroke was associated with lower 
levels of PDE3A. Therefore, although not conclusive, this 
finding is consistent with variants in the PDE3A locus influ-
encing expression of PDE3A in relevant tissues.
Discussion
We identified a genetic variant in the phosphodiesterase 3A 
gene that was associated at genome-wide significance with 
both FMD in early life and ischemic stroke. Colocalization 
analyses indicated that the same genetic variation in PDE3A 
associated with ischemic stroke is also associated with FMD, 
thereby showing the shared association is not merely coinci-
dental. The association with variants in PDE3A was consistent 
across all stroke subtypes, which are presumed to have distinct 
etiologies. It, therefore, seems probable that the variant acts 
Figure 2. Associations with PDE3A 
rs11045239 single-nucleotide polymorphism. 
Plot of the association of each risk allele 
(effect size and 95% CI) of the PDE3A 
rs11405239 single- nucleotide polymorphism 
on (A) cardiovascular risk factors and (B) 
cardiovascular disease outcomes and binary 
risk factor traits. Exact numbers of cases and 
controls were not available in publicly available 
data for ever smoking.
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via a risk factor common to all subtypes. Exploring association 
of the same genetic variant with multiple other cardiovascular 
risk factors and outcomes, we could find no association that the 
variant also acts via other independent processes. There was 
some suggestion that variants at the PDE3A locus influence ex-
pression of PDE3A in coronary arteries, although this was not 
conclusive. An interpretation consistent with these data is that 
the associated genetic locus influences expression of PDE3A in 
arterial tissues, which leads to altered endothelial function and 
subsequent risk of ischemic stroke. Mediation analysis might 
help to shed light on whether this is a potential causal pathway.
Although it is not possible to determine the exact mech-
anism by which the PDE3A variant confers risk of ischemic 
stroke and alters endothelial function without further experi-
mental data, some speculation on potential pathways is war-
ranted. In vascular smooth muscle, phosphodiesterases play a 
key role in the NO/cGMP pathway—one of the most important 
regulators of vascular smooth muscle contraction and platelet 
activation. NO activates sGC (soluble guanylyl cyclase), which 
activates cGMP, activating many signaling molecules, in par-
ticular, PRKG (protein kinase G), which in turn promotes 
vascular smooth muscle contraction. Phosphodiesterases de-
compose cGMP, as well as cAMP, into GMP and AMP, respec-
tively. This has the effect of monitoring the influence of cGMP 
on downstream processes such as smooth muscle contraction 
and platelet activation. Inhibition of phosphodiesterases has, 
therefore, been a target of multiple pharmaceuticals, with the 
intended effect of prolonging the influence of cGMP and pro-
moting vasodilation. One such pharmaceutical cilostazol is 
a selective inhibitor of phosphodiesterase type 3 and is used 
primarily to treat peripheral vascular disease. Studies in East 
Asian populations suggest it ameliorates endothelial dysfunc-
tion and reduces recurrent stroke rates in patients with pre-
vious stroke,32 although not all studies have been positive,33 
and it is currently being trialed for use to prevent recurrence 
after lacunar stroke in European populations.34 Off-label stud-
ies have also suggested it has the potential to prevent progres-
sion of intracranial arterial stenosis.35 However, PDE3A is also 
expressed in cardiac muscle, and whether the variant might in-
fluence stroke risk (particularly of cardioembolic source) via 
altered expression in the heart cannot be ruled out.
Why we detected an association of the PDE3A locus with 
endothelial function in adolescents, but not in adults, deserves 
further consideration. Aging has a considerable impact on en-
dothelial biology36,37; normal endothelial function in children 
has a different molecular basis to the (dysfunctional) endothe-
lium of older adults. In particular, decreases in NO produc-
tion, expression of endothelial NO synthase,38 expression of 
cell adhesions molecules such as ICAM1 (intercellular adhe-
sion molecule 1) and growth factors such as VEGF (vascular 
endothelial growth factor), as well as increases in levels of 
endothelin with age, contribute significant changes to endo-
thelial biology. Whether these factors lead to a fundamental 
change in the relationship between the PDE3A locus and 
endothelial function, or simply influence the signal-to-noise 
ratio and, therefore, our ability to detect an effect, remains un-
clear. Nevertheless, the fact that the same PDE3A locus has a 
subsequent influence on stroke risk suggests that the changes 
that occur in adolescence have a lasting impact on the vascu-
lature and subsequent pathological processes.
Our study has limitations. We demonstrate that genetic var-
iation that influences levels of PDE3A influences endothelial 
function and subsequently, ischemic stroke. As such, we demon-
strate a pathway by which risk of stroke conferred. However, we 
cannot rule out other horizontal pathways by which the PDE3A 
locus also leads to risk of ischemic stroke. However, we note that 
our analysis of other cardiovascular risk factors showed no asso-
ciation. As we were not able to assess endothelium-independent 
Table 1. Study Populations
Phenotype Study Sample Size
Ischemic stroke MEGASTROKE 60 341 cases and 
452 969 controls
FMD (young population) ALSPAC 5214
YFS  
  24–27 y 599
  24–45 y 2377
FMD (older population) MESA 1029
FHS 393
ALSPAC indicates Avon Longitudinal Study of Parents and Children; FHS, 
Framingham Heart Study; FMD, flow-mediated dilatation; MESA, Multi-Ethnic 
Study of Atherosclerosis; and YFS, Young Finns Study.
Table 2. Association of SNPs in Linkage Disequilibrium With rs11045239 With mRNA Expression of PDE3A in Coronary Arteries From Genotype-Tissue 
Expression (n=152)
SNP BP on Chromosome 12 Effect Allele Other Allele β P Value R2 With rs11045239
rs10841524 20589183 A G 0.13 0.0085 0.85
rs10841523 20588575 G A 0.13 0.012 0.85
rs11045245 20589390 A G 0.13 0.012 0.83
rs12811752 20577805 T C 0.11 0.026 0.93
rs12367495 20585416 C T 0.1 0.033 0.98
rs10841519 20584767 G C 0.1 0.037 1
rs7489190 20585027 G A 0.098 0.048 0.98
rs11045239 20579694 G A 0.089 0.075 1
β refers to the estimated influence of the effect allele of each SNP on mRNA expression of PDE3A. BP indicates base position; PDE3A, 
Phosphodiesterase 3A; and SNP, single-nucleotide polymorphism.
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vasodilation in response to a nitrate, we cannot be absolutely 
conclusive that our FMD measure results reflect endothelium-
dependent vasodilation. Rather, it is possible that they reflect 
nonspecific alterations in vascular reactivity.
Perspectives
In conclusion, we show that genetic variation in phosphodi-
esterase 3A leads to altered endothelial function in early life, 
mostly likely via expression of PDE3A, and also leads to 
increased risk of ischemic stroke, thus elucidating a pathway 
by which risk of disease is likely conferred.
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What Is New?
•	Using a large-scale genetic study of stroke (MEGASTROKE) and a study 
of endothelial function in adolescents (ALSPAC [Avon Longitudinal Study 
of Parents and Children]), we identified a genetic locus in the PDE3A 
gene, encoding phosphodiesterase 3A, that was associated with both 
endothelial function and ischemic stroke. The genetic variant was not 
associated with any other cardiovascular risk factor suggesting its influ-
ence on stroke acts solely through altered endothelial function.
What Is Relevant?
•	Our results highlight a pathway that in adolescence is influenced by ge-
netic variation, which influences risk of stroke in later life.
Summary
Genetic variation in PDE3A influences risk of stroke through altered 
endothelial function, as measured by flow-mediated dilatation.
Novelty and Significance
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